CYP3A5 polymorphism and sensitivity of blood pressure to dietary salt in Japanese men

Journal of Human Hypertension

Volumn 24, Issue 5, 2010, Pages 345-350

  Zhang, L ^a,b   Miyaki, K ^c   Wang, W ^a   Muramatsu, M ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Blood pressure; CYP3A5; Interaction; Polymorphism; Salt intake

Indexed keywords

ALANINE; CYTOCHROME P450 3A5; GLYCINE;

ADULT; AGE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; SALT INTAKE; SENSITIVITY ANALYSIS; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE;

ADULT; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; CULTURE; CYTOCHROME P-450 CYP3A; DIET; GENE FREQUENCY; GENOTYPE; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SODIUM CHLORIDE, DIETARY;

EID: 77951118721     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.74     Document Type: Article

References (23)

1. Paulussen A, Lavrijsen K, Bohets H, Hendrickx J, Verhasselt P, Luyten W et al. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 2000; 10: 415-424.
2. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001; 11: 111-121.
3. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996; 50: 52-59.
4. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O et al. Interindividual variability and tissuespecificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002; 30: 1108-1114.
5. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-779.
6. Thompson EE, Kuttab-Boulos H, Yang L, Roe BA, Di Rienzo A. Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics J 2006; 6: 105-114.
7. Beeks E, Kessels AG, Kroon AA, van der Klauw MM, de Leeuw PW. Genetic predisposition to saltsensitivity: a systematic review. J Hypertens 2004; 22: 1243-1249.
8. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004; 75: 1059-1069.
9. Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003; 95: 1297-1300.
10. Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF et al. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study. Am J Pharmacogenomics 2005; 5: 191-195.
11. Ho H, Pinto A, Hall SD, Flockhart DA, Li L, Skaar TC et al. Association between the CYP3A5 genotype and blood pressure. Hypertension 2005; 45: 294-298.
12. Shimazu T, Kuriyama S, Hozawa A, Ohmori K, Sato Y, Nakaya N et al. Dietary patterns and cardiovascular disease mortality in Japan: a prospective cohort study. Int J Epidemiol 2007; 36: 600-609.
13. Zhang L, Miyaki K, Araki J, Song Y, Kimura T, Omae K et al. Interaction of angiotensin I-converting enzyme insertion-deletion polymorphism and daily salt intake influences hypertension in Japanese men. Hypertens Res 2006; 29: 751-758.
14. Kawasaki T, Itoh K, Uezono K, Sasaki H. A simple method for estimating 24 h urinary sodium and potassium excretion from second morning voiding urine specimen in adults. Clin Exp Pharmacol Physiol 1993; 20: 7-14.
15. Chowbay B, Zhou S, Lee EJ. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev 2005; 37: 327-378.
16. Bochud M, Eap CB, Elston RC, Bovet P, Maillard M, Schild L et al. Association of CYP3A5 genotypes with blood pressure and renal function in African families. J Hypertens 2006; 24: 923-929.
17. Charlton KE, Steyn K, Levitt NS, Zulu JV, Jonathan D, Veldman FJ et al. Diet and blood pressure in South Africa: intake of foods containing sodium, potassium, calcium, and magnesium in three ethnic groups. Nutrition 2005; 21: 39-50.
18. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
19. Watlington CO, Kramer LB, Schuetz EG, Zilai J, Grogan WM, Guzelian P et al. Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats. Am J Physiol 1992; 262: F927-F931.
20. Morris DJ, Latif SA, Rokaw MD, Watlington CO, Johnson JP. A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy. Am J Physiol 1998; 274: C1245-C1252.
21. Weinberger MH, Fineberg NS, Fineberg SE,Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 2001; 37: 429-432.
22. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 1986; 8: II127-II134.
23. Eap CB, Bochud M, Elston RC, Bovet P, Maillard MP, Nussberger J et al. CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. Hypertension 2007; 49: 1007-1014.